PDCD1 and COVID-19: In COVID-19 patients, mononuclear cell PD-L1 transcript levels (3) and CD4+ T-cell surface PD-1 protein levels (4) are increased, possibly reflective of an evolving immunosuppressive response conducive to ICI therapy.